<code id='2CED6BE868'></code><style id='2CED6BE868'></style>
    • <acronym id='2CED6BE868'></acronym>
      <center id='2CED6BE868'><center id='2CED6BE868'><tfoot id='2CED6BE868'></tfoot></center><abbr id='2CED6BE868'><dir id='2CED6BE868'><tfoot id='2CED6BE868'></tfoot><noframes id='2CED6BE868'>

    • <optgroup id='2CED6BE868'><strike id='2CED6BE868'><sup id='2CED6BE868'></sup></strike><code id='2CED6BE868'></code></optgroup>
        1. <b id='2CED6BE868'><label id='2CED6BE868'><select id='2CED6BE868'><dt id='2CED6BE868'><span id='2CED6BE868'></span></dt></select></label></b><u id='2CED6BE868'></u>
          <i id='2CED6BE868'><strike id='2CED6BE868'><tt id='2CED6BE868'><pre id='2CED6BE868'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:explore    Page View:96484
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In